摘要
目的检测非小细胞肺癌(NSCLC)患者外周血CK19 mRNA的表达情况,探讨其作为分子标志物检测NSCLC微转移的可行性。方法应用逆转录聚合酶链反应(RT-PCR)技术检测48例NSCLC患者,15例肺良性疾病(BLD)患者和10例健康人外周血CK19 mRNA的表达。结果NSCLC患者CK19 mRNA的阳性表达率明显高于BLD患者和健康对照者,差异有统计学意义(χ2=24.735,P=0.000)。Ⅰ、Ⅱ、Ⅲ、Ⅳ期NSCLC患者外周血中CK19 mRNA阳性表达率分别为44.4%(8/18),75.0%(9/12),92.3%(12/13),4/5,不同临床分期NSCLC患者外周血CK19 mRNA阳性表达率比较差异有统计学意义(χ2=8.820,P=0.032);有无淋巴结转移NSCLC患者外周血CK19 mRNA阳性表达率比较差异亦有统计学意义(χ2=6.813,P=0.009);而不同病理类型、不同分化程度NSCLC患者外周血CK19 mRNA阳性表达率比较差异无统计学意义(χ2=4.655,P=0.459;χ2=1.204,P=0.548)。结论检测外周血CK19 mRNA表达可作为诊断NSCLC患者微转移的一个有价值的参考指标。
Objective To detect CK19 mRNA expression in peripheral blood of patients with non -small lung cancer （NSCLC） and discuss the possibility of indicating NSCLC mierometastases by it. Methods The expressions of peripheral blood CK19 mRNA were analyzed by reverse transcriptase -polymerase chain reaction （RT -PCR） for 48 NSCLC patients, 15 patients with benign lung disease （BLD） and 10 healthy volunteers. Results The expression positive rate of CK19 mRNA was significantly higher in NSCLC patients than those in BLD patients and healthy volunteers （X2 =24. 735, P =0. 000）. The expression rates of CK19 mRNA were 44.4% （8/18）, 75.0% （9/12）, 92.3% （12/13）, 4/5 in peripheral blood of patients with NSCLC of TNM stage Ⅰ , Ⅱ , Ⅲ, Ⅳ respectively. The positive expression of CK19 mRNA was significantly related with the clinical staging （ Х^2 = 8. 820, P = 0. 032） and lymph node metastasis （ Х^2 = 6. 813, P = 0. 009）, but not significantly related to pathological typing （ Х^2= 4. 655, P = 0. 459 ） and tumor cell differentiation （Х^2 = 1. 204, P = 0. 548 ）. Conclusion The expressions of CK19 mRNA in peripheral blood can be used as a valuable biomarker for diagnosis of micrometastasis in patients with NSCLC.
出处
《中国全科医学》
CAS
CSCD
北大核心
2010年第1期42-44,共3页
Chinese General Practice
基金
广西壮族自治区科技厅自然基金(桂科自0542078)
广西壮族自治区科技厅青年基金(桂科青0728067)
